BMN-673 8R,9S|Talazoparib (8R,9S)|DC Chemicals

Cas No.:	1207456-00-5
Synonyms:	Talazoparib (8R,9S); (8R,9S)-BMN-673; BMN673 (8R,9S); BMN 673 (8R,9S)
SMILES:	FC1=CC=C(C2C(C3N(C)N=CN=3)C3=NN=C(O)C4C3C(C=C(C=4)F)=N2)C=C1
Formula:	C₁₉H₁₄F₂N₆O
M.Wt:	380.35
Purity:	>95%，ee>92%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks. BMN-673 has been proven to be highly active in mouse models of human cancer and also appears to be more selectively cytotoxic with a longer half-life and better bioavailability as compared to other compounds in development. For the detailed information of BMN-673 8R,9S, the solubility of BMN-673 8R,9S in water, the solubility of BMN-673 8R,9S in DMSO, the solubility of BMN-673 8R,9S in PBS buffer, the animal experiment (test) of BMN-673 8R,9S, the cell expriment (test) of BMN-673 8R,9S, the in vivo, in vitro and clinical trial test of BMN-673 8R,9S, the EC50, IC50,and affinity,of BMN-673 8R,9S, For the detailed information of BMN-673 8R,9S, the solubility of BMN-673 8R,9S in water, the solubility of BMN-673 8R,9S in DMSO, the solubility of BMN-673 8R,9S in PBS buffer, the animal experiment (test) of BMN-673 8R,9S, the cell expriment (test) of BMN-673 8R,9S, the in vivo, in vitro and clinical trial test of BMN-673 8R,9S, the EC50, IC50,and affinity,of BMN-673 8R,9S, Please contact DC Chemicals.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC47395	CEP-9722	CEP-9722, the prodrug of CEP-8983, is a selective and orally active PARP-1 and PARP-2 inhibitor with IC50s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects.
DC47394	PARP1-IN-6	PARP1-IN-6 is a dual tubulin/PARP-1 inhibitor with IC50 values of 0.94 and 0.48 μM, respectively.
DC47393	PARP/EZH2-IN-1	PARP/EZH2-IN-1 is a first-in-class dual PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.
DC47211	TC-E 5001	TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively.
DC46429	PARP1-IN-5	PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 can be used for the research of cancer.
DC46428	PARP1-IN-5 dihydrochloride	PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer.
DC45192	Olaparib D8	Olaparib D8 (AZD2281 D8) is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator.
DC42488	2-Methylquinazolin-4-ol	2-Methylquinazolin-4-ol is a potent competitive poly(ADP-ribose) synthetase inhibitor, with a Ki of 1.1 μM. 2-Methylquinazolin-4-ol mammalian aspartate transcarbamylase (ATCase) inhibitor, with 0.20 mM.
DC42294	Senaparib	Senaparib (IMP4297) is a highly potent, selective and orally active PARP1/2. Senaparib (IMP4297) exhibits strong antitumor activity in animal models.
DC40457	Fluorescein-NAD+	Fluorescein-NAD+ is an alternative to radiolabeled NAD and a substrate for ADP-ribosylation. Fluorescein-NAD+ can be used in PARP assays by fluorescence microscopy. Extinction Coefficient: 262 nm.